Search Results

out of 6 results
DAWN | Drug Abuse Warning Network
Collected Date: 2005-2011
Report Type: Spotlight

This spotlight report describes the risks of combining the drug Ecstasy (also known as MDMA or methylenedioxymethamphetamine) with alcohol. For emergency department patients aged 20 and younger, it provides the number of emergency department visits that involved Ecstasy, and the percentage of Ecstasy-related visits that involved alcohol for the years...

DAWN | Drug Abuse Warning Network
Collected Date: 2011
Report Type: Spotlight

This report is about ER visits involving 'bath salts,' a new type of stimulant drug, and describes what types of drugs are most commonly combined with 'bath salts' in ER visits.

DAWN | Drug Abuse Warning Network
Collected Date: 2005-2011
Report Type: Spotlight

This Drug Abuse Warning Network (DAWN) spotlight is about emergency department visits involving nonmedical use of central nervous system stimulants among adults age 18 to 34 increase between 2005 and 2011.

DAWN | Drug Abuse Warning Network
Collected Date: 2005-2010
Report Type: Spotlight

This Drug Abuse Warning Network (DAWN) spotlight is about emergency department visits involving marijuana among adolescents aged 15 to 17 increase from 2005 to 2010 varied by gender.

DAWN | Drug Abuse Warning Network
Collected Date: 2011
Report Type: Spotlight

This Drug Abuse Warning Network (DAWN) spotlight looks at the outcomes of emergency department visits that involve underage drinking in 2011. The report compares the outcome of emergency department vists by patients ages 12-20 that involved alcohol only, to visits where other drug(s) were taken along with alcohol.

DAWN | Drug Abuse Warning Network
Collected Date: 2011
Report Type: Spotlight

This report describes emergency department (ED) visits involving drug-related suicide attempts using data from the 2011 Drug Abuse Warning Network (DAWN). The ED visits for suicide attempts by middle-aged adults were more likely to involve alcohol combined with other drugs compared with other drug-related visits.